Slide from Katherine Tuttles presentation, during FLOW session, 61st European Renal Association Congress Conclusion The FLOW trial showed that semaglutide significantly decreased the risk of progression of kidney disease in T2DM, without significant increases in serious adverse events
Glycogen is the bodys primary fuel source for moderate to high intensity exercise, and when total food intake decreases, carbohydrate intake often falls with it
Frontiers in Endocrinology, 14, 1184302
They can help you navigate potential interactions and ensure that your treatment plan is safe and effective
Treatment was associated with fibrosis improvement by at least one stage with no worsening in non-alcoholic fatty liver disease (NAFLD) activity score in 25% of resmetirom recipients versus just under 15% in the placebo group
Some people experience persistent fatigue , headaches , or anxiety that does not resolve with dose adjustments